Disease Overview：ALK-Fusion NSCLC（ALK+ NSCLC）
ALK fusion-positive non-small cell lung cancer (NSCLC) is a molecularly defined subtype of lung adenocarcinoma characterized by chromosomal rearrangements involving the anaplastic lymphoma kinase (ALK) gene—most commonly the EML4-ALK fusion. Present in approximately 3–5% of NSCLC cases, it predominantly affects younger, never- or light-smokers and exhibits distinct clinical behavior and high sensitivity to targeted ALK tyrosine kinase inhibitors (TKIs). First-line therapy typically involves next-generation ALK inhibitors such as alectinib, brigatinib, or lorlatinib, which demonstrate superior central nervous system penetration and progression-free survival compared to older agents like crizotinib. Resistance mechanisms—including secondary ALK mutations and bypass pathway activation—guide sequential treatment strategies, often supported by comprehensive genomic profiling via NGS-based tissue or liquid biopsy.
China offers compelling advantages for international patients seeking ALK+ NSCLC care: leading oncology centers—such as Fudan University Shanghai Cancer Center and Peking Union Medical College Hospital—house nationally certified molecular tumor boards and FDA/CFDA-approved ALK inhibitor access, including early availability of lorlatinib and ensartinib. Advanced platforms like digital pathology, AI-assisted radiomics, and real-time ctDNA monitoring enhance precision decision-making. Clinical outcomes align with global benchmarks: multi-center studies report median PFS exceeding 34 months with alectinib and >70% intracranial response rates with lorlatinib. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising regulatory rigor or multidisciplinary standards.
As a dedicated medical tourism agency, we facilitate seamless international patient journeys—vetting accredited hospitals, coordinating molecular testing and TKI procurement, providing transparent all-inclusive pricing, and delivering end-to-end support from visa assistance to post-treatment follow-up coordination.
ALK-Fusion NSCLC: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: ALK+ Non-Small Cell Lung Cancer (NSCLC)
I. Targeted Therapy (First-Line & Subsequent Lines)
*Eligibility*: Confirmed *ALK* fusion (via IHC/FISH/NGS); ECOG PS 0–2; no contraindications to oral TKIs.
- •Alectinib (1st-line): ¥23,800/month → $3,300
- •Brigatinib (1st-line or post-crizotinib): ¥29,500/month → $4,100
- •Lorlatinib (3rd-line+, CNS metastases): ¥34,200/month → $4,750
II. Chemotherapy ± Immunotherapy (Limited Use)
*Eligibility*: TKI intolerance, rapid progression, or *ALK* resistance with high PD-L1 (>50%) and no actionable resistance mutations.
- •Pemetrexed + Carboplatin (q3w × 4 cycles): ¥18,500/cycle → $2,570
- •Pembrolizumab + chemo (if PD-L1 ≥50%): ¥22,300/cycle → $3,100
III. Surgical Resection (Stage I–IIIA, resectable)
*Eligibility*: Clinical stage T1–3N0–1M0; adequate pulmonary reserve (FEV1 >1.5 L, DLCO >50%); no *ALK*-TKI resistance prior to surgery.
- •Preoperative Workup: ¥4,200 → $580
- •Video-Assisted Thoracoscopic Surgery (VATS) Lobectomy: ¥48,000–¥62,000 → $6,700–$8,600
- •Open Lobectomy (if VATS contraindicated): ¥55,000–¥71,000 → $7,700–$9,900
IV. Radiation for Oligoprogressive Disease or CNS Metastases
*Eligibility*: ≤3 intracranial lesions (<3 cm), or symptomatic bone/lymph node progression on TKI.
- •Stereotactic Radiosurgery (SRS) for brain mets: ¥12,000–¥18,000 → $1,700–$2,500
- •SBRT for oligometastatic lung/bone: ¥15,500–¥21,000 → $2,200–$2,900
V. Quick Selection Guide
- •Younger patient (<65), fit, newly diagnosed: Start alectinib ($3,300/mo) — optimal PFS, CNS penetration, tolerability.
- •Elderly (>75) or frail (ECOG ≥2): brigatinib ($4,100/mo) — lower edema risk than alectinib; avoid surgery/radiation unless urgent symptom control.
- •Budget-constrained (<$2,000/mo): Enroll in national drug assistance program (alectinib co-pay reduced to ¥3,500/mo → $490) after initial NGS confirmation (¥4,800 → $670).
- •CNS progression on 1st-gen TKI: Switch to lorlatinib ($4,750/mo) + concurrent SRS ($1,700–$2,500) — highest intracranial response rate.
- •Resectable early-stage disease: VATS lobectomy ($6,700–$8,600) followed by adjuvant alectinib (3 years, $3,300/mo) — curative-intent standard.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended ALK-Fusion NSCLC Medical Vacation Packages
Curated transparent all-inclusive packages combining ALK-Fusion NSCLC treatment with China top medical destinations:
